Pii Introduces the Accelevate™ Early Development Platform
Pharmaceutics International, Inc. (Pii), a highly regarded provider of pharmaceutical development and manufacturing services, has made a significant announcement regarding the launch of its innovative Accelevate™ Early Development Platform. This advanced platform is specifically crafted to hasten the preparation of Investigational New Drug (IND) submissions, granting small to mid-sized pharmaceutical companies the capability to achieve IND readiness in just 100 days for aseptic products.
The Growing Demand for Early-Phase Development Services
With the global market for early-phase development services now valued at an estimated $15 billion, the Accelevate™ platform is perfectly positioned to cater to the increasing demand for expedited drug development solutions. By tackling the challenges often faced by smaller pharmaceutical companies, Accelevate™ provides a significant competitive edge, allowing these companies to shorten time-to-market while ensuring adherence to rigorous quality and compliance standards.
Addressing Industry Challenges
The introduction of the Accelevate™ platform comes at a crucial time when the pressure on the pharmaceutical industry to minimize time-to-market has intensified. This is particularly true for smaller businesses that may not possess the necessary internal resources to effectively manage the complexities associated with early-stage development. Accelevate™ integrates Pii’s cutting-edge technology, regulatory proficiency, and project management expertise to create a streamlined, efficient pathway from molecule identification to IND submission.
Expert Insight on Accelevate™
Travis Webb, the Chief Scientific Officer of Pii, highlighted the pivotal role this platform plays in today’s pharmaceutical landscape. He stated, “Accelevate™ embodies a transformative leap for smaller pharmaceutical companies, equipping them to progress through the early development phase with unmatched speed. We are empowering these companies to remain competitive in a rapidly evolving market by significantly expediting the IND submission timeline without reducing regulatory compliance.”
Innovative Technologies at Work
The Accelevate™ platform employs advanced in silico modeling and machine learning techniques to streamline the development process. This ensures that data generation is both rapid and precise while adhering to the strict guidelines set forth by regulatory bodies such as the FDA, EMA, and ICH. The platform provides extensive support, encompassing pre-clinical studies, toxicology, pharmacokinetics, and safety evaluations, in addition to expert regulatory guidance and essential documentation for IND submissions. Clients can expect a dedicated project management team from Pii to oversee coordination among various functions, ensuring the accomplishment of critical development milestones within the ambitious 100-day timeline.
Setting New Standards with Accelevate™
Pii’s unwavering commitment to innovation and excellence is exemplified with the launch of the Accelevate™ platform. This development is set to redefine standards for speed and efficiency in early-stage pharmaceutical development. By providing a quick and seamless route to IND submission, Pii is reinforcing its position as a reliable partner, enabling pharmaceutical companies to introduce new therapies to the market with greater speed and confidence.
About Pharmaceutics International, Inc.
Founded in 1994 by Dr. Syed Abidi, a pioneering formulation scientist, Pharmaceutics International, Inc. (Pii) stands as a prominent Contract Development and Manufacturing Organization (CDMO) specializing in comprehensive solutions for aseptic and oral dosage forms. With over 30 years of experience managing complex formulations, including potent compounds and controlled substances, Pii operates from Hunt Valley, MD. The organization’s offerings encompass lyophilization, high potency isolation, and robotic filling. With a strong focus on maintaining the highest quality and safety standards, Pii supports small to medium-volume projects with flexible, scalable solutions. The company's mission is to enhance quality of life through innovative and superior pharmaceuticals.
Frequently Asked Questions
What is the Accelevate™ platform?
The Accelevate™ platform is designed to expedite the preparation of Investigational New Drug submissions, targeting a 100-day timeline for aseptic products.
Who can benefit from the Accelevate™ platform?
Small to mid-sized pharmaceutical companies looking to accelerate their drug development processes can greatly benefit from this innovative platform.
How does Accelevate™ improve the drug development process?
By integrating advanced technology, regulatory expertise, and effective project management, Accelevate™ streamlines the transition from molecule identification to IND submission.
What technologies are utilized in Accelevate™?
The platform leverages in silico modeling and machine learning to enhance data generation and ensure compliance with regulatory guidelines.
Who founded Pharmaceutics International, Inc.?
Pii was founded by Dr. Syed Abidi, a notable formulation scientist, and has been operating since 1994.
